MRUS - Merus N.V.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
15.09
+1.08 (+7.71%)
As of 2:30PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close14.01
Open13.95
Bid13.67 x 800
Ask14.01 x 1100
Day's Range13.79 - 15.09
52 Week Range12.00 - 26.74
Volume21,665
Avg. Volume38,998
Market Cap341.529M
Beta (3Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Incyte Advances R&D Strategy with Multiple Partnerships
    Market Realist7 months ago

    Incyte Advances R&D Strategy with Multiple Partnerships

    In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN), which was later amended in February 2017. As per the amended agreement, the ongoing research programs for the development of checkpoint modulator antibodies targeted at GITR and OX40 have been converted from co-funded ones to being fully funded by Incyte. Additionally, the profit-sharing arrangement for these research programs has been converted into royalty-bearing programs.

  • Merus' Antibody Candidate in Phase II Breast Cancer Study
    Zacks10 months ago

    Merus' Antibody Candidate in Phase II Breast Cancer Study

    Merus (MRUS) initiates a phase II study to evaluate its most advanced pipeline candidate in advanced breast cancer.

  • Reuters10 months ago

    BRIEF-Merus And Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies

    Jan 8 (Reuters) - Simcere Pharmaceutical Group (IPO-SMPT.HK): * MERUS AND SIMCERE ANNOUNCE STRATEGIC COLLABORATION ON MULTIPLE BISPECIFIC ANTIBODIES * MERUS - AGREED TO GRANT SIMCERE EXCLUSIVE LICENSE ...

  • Merus NV (NASDAQ:MRUS): Should The Future Outlook Worry You?
    Simply Wall St.11 months ago

    Merus NV (NASDAQ:MRUS): Should The Future Outlook Worry You?

    The most recent earnings announcement Merus NV’s (NASDAQ:MRUS) released in September 2017 suggested that losses became smaller relative to the prrior year’s level as a result of recent tailwinds Below,Read More...

  • Merus NV :MRUS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
    Capital Cube11 months ago

    Merus NV :MRUS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Merus NV reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Merus NV – Pieris Pharmaceuticals, Inc. and PDL BioPharma, Inc. (PIRS-US and PDLI-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 4.05 million, Net ... Read more (Read more...)

  • Capital Cubelast year

    Merus NV – Value Analysis (NASDAQ:MRUS) : November 29, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Merus NV a score of 29. Our analysis is based on comparing Merus NV with the following peers – P&P Ventures, Inc., Plandai Biotechnology, Inc., Pieris Pharmaceuticals, Inc. and PDL BioPharma, Inc. (PPV.H-CA, PLPL-US, PIRS-US and PDLI-US). Investment Outlook Merus NV has a fundamental score of 29 ... Read more (Read more...)

  • Merus NV breached its 50 day moving average in a Bullish Manner : MRUS-US : November 28, 2017
    Capital Cubelast year

    Merus NV breached its 50 day moving average in a Bullish Manner : MRUS-US : November 28, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Merus NV. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)